Abstract
Once prostate cancer becomes castration resistant, cancer cells may rapidly gain the ability to invade and to metastasize to lymph nodes and distant organs. The progression through hormone-dependent to hormone-independent/ castration-resistant and metastatic PCa is poorly understood. In this review paper, we provide an overview on the cellular and molecular mechanisms underlying the process of tumor cell invasion and metastasis in prostate cancer. We specifically presented the most recent findings on the role of multiple cellular signaling pathways including androgen receptor (AR), mitogen-activated protein kinases (MAPK), Akt, transforming growth factor β (TGFβ), interleukin-6 (IL- 6) and vascular endothelial growth factor (VEGF) in the development of hormone-independent/castration-resistant prostate cancer. In addition, we also discussed the recent findings on signatures of gene expression during prostate cancer progression. Our overviews on the novel findings will help to gain better understanding of the complexity of molecular mechanisms that may play an essential role for the development of castration-resistant and metastatic prostate cancer. It will also shed light on the identifying specific targets and design effective therapeutic drug candidates.
Keywords: Prostate cancer, androgen receptor, molecular pathways, castration resistance
Current Cancer Drug Targets
Title: Molecular Pathways in the Progression of Hormone-Independent and Metastatic Prostate Cancer
Volume: 10 Issue: 4
Author(s): B. Wegiel, S. Evans, R. Hellsten, L.E. Otterbein, A. Bjartell and J.L. Persson
Affiliation:
Keywords: Prostate cancer, androgen receptor, molecular pathways, castration resistance
Abstract: Once prostate cancer becomes castration resistant, cancer cells may rapidly gain the ability to invade and to metastasize to lymph nodes and distant organs. The progression through hormone-dependent to hormone-independent/ castration-resistant and metastatic PCa is poorly understood. In this review paper, we provide an overview on the cellular and molecular mechanisms underlying the process of tumor cell invasion and metastasis in prostate cancer. We specifically presented the most recent findings on the role of multiple cellular signaling pathways including androgen receptor (AR), mitogen-activated protein kinases (MAPK), Akt, transforming growth factor β (TGFβ), interleukin-6 (IL- 6) and vascular endothelial growth factor (VEGF) in the development of hormone-independent/castration-resistant prostate cancer. In addition, we also discussed the recent findings on signatures of gene expression during prostate cancer progression. Our overviews on the novel findings will help to gain better understanding of the complexity of molecular mechanisms that may play an essential role for the development of castration-resistant and metastatic prostate cancer. It will also shed light on the identifying specific targets and design effective therapeutic drug candidates.
Export Options
About this article
Cite this article as:
Wegiel B., Evans S., Hellsten R., Otterbein L.E., Bjartell A. and Persson J.L., Molecular Pathways in the Progression of Hormone-Independent and Metastatic Prostate Cancer, Current Cancer Drug Targets 2010; 10 (4) . https://dx.doi.org/10.2174/156800910791208562
DOI https://dx.doi.org/10.2174/156800910791208562 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Molecular-Targeted Therapeutics for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry A Review on Extraction, Synthesis and Anticancer Activity of Betulinic Acid
Current Bioactive Compounds Let-7a Could Serve as A Biomarker for Chemo-Responsiveness to Docetaxel in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry The Application of Mass Spectrometry to Proteomics and Metabolomics in Biomarker Discovery and Drug Development
Current Molecular Pharmacology In vitro Evaluation of Gadolinium-Silica Mesoporous Nanoparticles- Monoclonal Antibody: Potential Nanoprobe for Prostate Cancer Cell Imaging
Current Molecular Imaging (Discontinued) Prevention and Treatment of Cardiovascular Disease in Adolescents and Adults through the Transcendental Meditation® Program: A Research Review Update
Current Hypertension Reviews Estrogen Catechols Detection as Biomarkers in Schistosomiasis Induced Cancer and Infertility
Letters in Drug Design & Discovery Biochemical Properties of Indoleamine 2,3-dioxygenase: From Structure to Optimized Design of Inhibitors
Current Medicinal Chemistry Molecular Delivery of Plasmids for Genetic Vaccination
Current Pharmaceutical Biotechnology Recent Advances of Hepsin-Targeted Inhibitors
Current Medicinal Chemistry Therapeutic Potential of Small Activating RNAs (saRNAs) in Human Cancers
Current Pharmaceutical Biotechnology Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Study of drug-drug combinations based on molecular descriptors and physicochemical properties
Combinatorial Chemistry & High Throughput Screening CXCR4 Receptor as a Promising Target for Oncolytic Drugs
Mini-Reviews in Medicinal Chemistry Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: A Novel Molecular Target Against Age-Related Diseases
Current Medicinal Chemistry Therapeutic Strategies for Treatment of Inflammation-related Depression
Current Neuropharmacology Improving Cancer Chemotherapy with Modulators of ABC Drug Transporters
Current Drug Targets Repulsive Guidance Molecules (RGMs) and Their Potential Implication in Cancer as Co-receptor of BMPs
Current Signal Transduction Therapy HSP60 as a Drug Target
Current Pharmaceutical Design Genetic Alterations in Differentiated Thyroid Cancers
Endocrine, Metabolic & Immune Disorders - Drug Targets